Daunomycin (10 μmol/h/kg) | Taurocholate (400 pmol/h/kg) | E217 βG (160 pmol/h/kg) | ||||
---|---|---|---|---|---|---|
Normal | CCl4-EHI24 h | Normal | CCl4-EHI24 h | Normal | CCl4-EHI24 h | |
Plasma concentration (P) | 2.30 ± 0.24 μM | 2.00 ± 0.13 μM | 0.288 ± 0.027 nM | 0.350 ± 0.013 nM3-150 | 0.151 ± 0.012 nM | 0.263 ± 0.011 nM 3-150 |
Liver concentration (L) | 36.1 ± 3.3 μM | 21.1 ± 4.0 μM3-150 | 1.39 ± 0.30 nM | 1.26 ± 0.13 nM | 0.409 ± 0.12 nM | 0.792 ± 0.19 nM3-150 |
Biliary excretion rate | 7.14 ± 0.79 nmol/min/kg | 7.99 ± 1.5 nmol/min/kg | 5.20 ± 0.62 pmol/min/kg | 5.44 ± 1.2 pmol/min/kg | 1.35 ± 0.15 pmol/min/kg | 1.60 ± 0.13 pmol/min/kg |
CLexc(ml/min/kg)3-b | 0.198 ± 0.015 | 0.353 ± 0.0613-150 | 3.74 ± 0.91 | 4.22 ± 0.64 | 3.57 ± 0.38 | 2.12 ± 0.493-150 |
Summary of the Effects of CCl4 on the Pharmacokinetic Parameters of daunomycin, taurocholate, and E217 βG at steady-state conditionsa.